The global study, presented this week at the American Society of Clinical Oncology annual conference in Chicago, involved a total of 121 patients.Ī total of 59 were enrolled in the branch of the phase two clinical trial dedicated to assessing the drug cocktail’s effectiveness, with 29 getting the experimental pairing. More likely to affect younger womenĪround 700 women a year will be diagnosed with LGSCO every year in the UK and it is more likely to affect younger women than other forms of ovarian cancer. LGSOC is an uncommon form of the condition and makes up around one in 10 of all ovarian cancer cases. It is hoped that the discovery will double the number of patients who can be treated for the disease. However, a study from Royal Marsden Hospital’s cancer experts has found that a course of two drugs together has a response rate of almost half (45 per cent). A cocktail of two drugs could offer twice as many women suffering with a rare form of ovarian cancer hope of treatment, according to a new study.Ĭurrently, only a quarter (26 per cent) of women diagnosed with a type of ovarian cancer called low-grade serous ovarian cancer (LGSOC) will respond to the best available treatment.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |